Address: Archimedesstraat 11 – B1000 Brussels,Belgium
Tel: +32 2 285 42 00
Web: http://www.apb.be/Content/Default.asp
The General Pharmaceutical Association (APB) is the umbrella federation of the Belgian associations of independent pharmacists. APB represents 90 percent of the pharmaceutical corps, which essentially covers the total of the corresponding independent pharmacists.
The activities of the APB includes the advocacy of its members as well as other forms of assistance and information to its members.
Under the control of the General Assembly shall determine the general policy of the Federal Council, which is followed by the Management Committee. This includes not only ‘contacts’ with the Federal Government, Regions, Communities and the official authorities, but also the representation in the lap of numerous committees both at regulatory level and in terms of the health of the drug delivery control.
The APB members provide services including legal assistance, social and economic information, scientific and pharmaceutical documentation, etc.
In addition, the Office for Drug Research (DGO) part of the APB. The core of this officially recognized and accredited laboratory analysis, monitoring and systematic, periodic rechecking of medicines and products with a quality label.
PharmaBoardroom was delighted to attend DIA Europe 2024 in Brussels earlier this month, bringing together a veritable who’s-who of the European and global regulatory community. The politicians, regulators, payers, patient…
Belgium, one of Europe’s most important countries for biopharmaceutical production and R&D, assumed presidency of the Council of the European Union on the first of January. As part of its…
A new piece in the January 2023 edition of DIA’s Global Forum magazine lays out how a new coalition aims to transform the landscape for rare disease treatments in Europe…
UCB has been undergoing a far-reaching digital business transformation, integrating novel approaches across its R&D organisation, including Computer-Aided Drug Design (CADD) and AI, while striving to maintain a patient-centric focus.…
Pfizer’s David Isom and Monica Mihedji, writing in the November 2023 edition of the DIA’s Global Forum magazine, examine how the European Medicines Agency is attempting to integrate the use…
Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities…
The European Coalition for Access to Comprehensive Genomic Profiling (ECGP) is a new initiative made up of industry association the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), molecular diagnostics firms Exact…
Janssen has the lofty aim of reaching USD 60bn dollars in sales by 2025, an 8bn increase on the 2021 figure, despite some high-profile losses of exclusivity and the spin-off…
There have been both ups and downs in AbbVie’s recent history. After proving its staying power with the celebration of its 10-year anniversary as an independent company spun off from…
Representatives of Belgian associations for innovative pharma, generics and biosimilars, medtech, OTC, biotech, hospitals, and medical professionals share their key agenda priorities. These include where they feel that change is…
Germany and Belgium have long held an important trading relationship, says Margit Kunz of AHK Debelux, the German chamber of commerce in Belgium and Luxembourg. She outlines some of the…
Perhaps to the surprise of many, Belgium is the world’s second-largest producer of vaccines, behind only the US, and – capitalising on its years of experience in the field –…
See our Cookie Privacy Policy Here
